• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Betterlife Pharma Inc (OP:BETRF)

    0.0450 -0.0030 (-6.25%)
    Streaming Delayed Price Updated: 12:03 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Betterlife Pharma Inc

    < Previous 1 2 Next >
    BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
    World's Largest Psychedelics Conference Boasts 12K Attendees 
    Via Benzinga
    BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
    Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S. 
    Via Benzinga
    BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
    Science Conference In Dubai, UAE Hosts Discussion On Psychedelics Research 
    Via Benzinga
    BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
    Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies  toward expected clinical studies targeting... 
    Via Benzinga
    BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Continues Progress on BETR-001 IND-Enabling Studies
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
    Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
    Via Benzinga
    Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic
    The next-generation psychedelics R&D business is up and running, as BetterLife Pharma Inc. 
    Via Benzinga
    BetterLife Engages Canadian Healthcare Investment Firm, Aims For Clinical Trial Programs
    BetterLife Pharma (OTCQB: BETRF), a non-hallucinogenic psychedelics biotech company, has contracted Bloom Burton Securities Inc. for strategic advisory services. 
    Via Benzinga
    BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife Announces Closing of Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives
    In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings. 
    Via Benzinga
    Study Reveals BetterLife's LSD Analogue Boosts Structural Neuroplasticity Without Hallucinogenic Side Effects
    A recent paper has provided new evidence that LSD has outstanding nootropic effects, believed to originate in the drug’s neuroplasticity promotion, in both animals and humans. 
    Via Benzinga
    BetterLife's Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs
    Biotech psychedelics company BetterLife Pharma Inc. (OTCQB: BETRF) in collaboration with the Carleton University Dept. 
    Via Benzinga
    EXCLUSIVE: Can Non-Hallucinogenic Psychedelic Compounds Treat Mental Health Conditions? This Company Thinks So!
    Image Provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
    Via Benzinga
    What Do You Really Know About Psychedelics And Psychedelics Stocks?
    According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That... 
    Via Benzinga
    Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
    The Week In Psychedelics 
    Via Benzinga
    There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
    Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
    Via Benzinga
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.